NasdaqGS:QURE - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	130	-170	-107	-108	8
12/31/2025	95	-181	-135	-167	12
12/31/2024	53	-235	-196	-193	12
3/31/2024	19	-297	-135	-128	N/A
12/31/2023	16	-308	-153	-146	N/A
9/30/2023	112	-228	-161	-151	N/A
6/30/2023	112	-187	-251	-239	N/A
3/31/2023	110	-157	-214	-198	N/A
12/31/2022	106	-127	-163	-145	N/A
9/30/2022	61	-125	-154	-137	N/A
6/30/2022	62	-114	-149	-129	N/A
3/31/2022	525	324	286	304	N/A
12/31/2021	524	330	271	288	N/A
9/30/2021	500	321	281	298	N/A
6/30/2021	500	303	292	303	N/A
3/31/2021	38	-139	-154	-143	N/A
12/31/2020	38	-125	-144	-135	N/A
9/30/2020	6	-166	-132	-124	N/A
6/30/2020	5	-136	-120	-111	N/A
3/31/2020	6	-124	-114	-105	N/A
12/31/2019	7	-124	-105	-99	N/A
9/30/2019	6	-105	-96	-91	N/A
6/30/2019	8	-103	-93	-89	N/A
3/31/2019	9	-92	-86	-81	N/A
12/31/2018	11	-83	-80	-76	N/A
9/30/2018	12	-90	-81	-76	N/A
6/30/2018	11	-78	-76	-71	N/A
3/31/2018	13	-78	-78	-74	N/A
12/31/2017	13	-79	N/A	-64	N/A
9/30/2017	20	-67	N/A	-62	N/A
6/30/2017	25	-72	N/A	-65	N/A
3/31/2017	24	-71	N/A	-68	N/A
12/31/2016	25	-73	N/A	-72	N/A
9/30/2016	20	-76	N/A	-81	N/A
6/30/2016	16	-90	N/A	-62	N/A
3/31/2016	14	-90	N/A	5	N/A
12/31/2015	11	-82	N/A	7	N/A
9/30/2015	8	-76	N/A	22	N/A
6/30/2015	6	-58	N/A	13	N/A
3/31/2015	5	-45	N/A	-35	N/A
12/31/2014	6	-50	N/A	-37	N/A
9/30/2014	5	-41	N/A	-29	N/A
6/30/2014	6	-42	N/A	-6	N/A
3/31/2014	6	-41	N/A	-7	N/A
12/31/2013	4	-37	N/A	-6	N/A
9/30/2013	3	-33	N/A	-1	N/A
6/30/2013	1	-27	N/A	-18	N/A

애널리스트 미래 성장 예측

수입 대 저축률: QURE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: QURE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: QURE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: QURE 의 수익(연간 38.9% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: QURE 의 수익(연간 38.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: QURE 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

uniQure 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates fall by 15%

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Consensus revenue estimates decrease by 33%, EPS upgraded

Consensus revenue estimates fall by 35%

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 55%

Recent updates

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 15%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

uniQure N.V., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director

CEO & Executive Director recently sold US$177k worth of stock

Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Executive Director notifies of intention to sell stock

Consensus revenue estimates decrease by 33%, EPS upgraded

New minor risk - Share price stability

uniQure: The Valuation Got More Attractive

Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding

uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease

A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Consensus revenue estimates fall by 35%

uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 55%

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Operating Officer notifies of intention to sell stock

uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough

Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher

uniQure N.V. Announces Executive Changes

New minor risk - Share price stability

Consensus revenue estimates increase by 12%

Consensus revenue estimates fall by 36%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

CEO & Executive Director notifies of intention to sell stock

Consensus EPS estimates fall by 16%

CEO & Executive Director recently sold US$493k worth of stock

CEO & Executive Director notifies of intention to sell stock

News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Independent Non-Executive Director exercised options and sold US$103k worth of stock

Independent Non-Executive Director exercised options and sold US$143k worth of stock

CEO & Executive Director recently sold US$149k worth of stock

Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?

Independent Non-Executive Director notifies of intention to sell stock

uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Consensus revenue estimates fall by 51%

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Insider exercised options and sold US$123k worth of stock

Investor sentiment improved over the past week

uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Investor sentiment improved over the past week

Chief Operating Officer recently sold US$100k worth of stock

Chief Operating Officer notifies of intention to sell stock

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

Consensus revenue estimates fall by 44%